Tags

Type your tag names separated by a space and hit enter

Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy.
Pediatr Blood Cancer. 2010 May; 54(5):716-20.PB

Abstract

PURPOSE

The aim of this study was to assess the immune response of children with acute lymphoblastic leukemia (ALL) to influenza vaccine and to compare it with healthy controls.

PROCEDURE

Thirty-two children aged 1-18 years with ALL on maintenance therapy and 30 healthy sibling controls were enrolled in the study. All children were vaccinated with trivalent inactivated influenza vaccine. Hemagglutinin-inhibition (HI) antibody titers were determined in sera of both patient and control groups just before and 4 weeks after vaccination. The ability of each group to mount a protective (> or =40) and/or fourfold titer was measured.

RESULTS

The protective response for virus subunits among patients and healthy controls were 43.4% versus 88% for H1N1 (P = 0.04), 63.3% versus 80% for H3N2 antigens (P = 0.06), and 26% versus 73% for B antigen (P = 0.001). Responses for H1N1 and B subunits were significantly lower in patients than controls. In the patient group, the significant response to each virus was demonstrated in the analysis of pre- and post-vaccination geometric mean titer (GMT) (P = 0.001). The percentage of patients and controls with fourfold increase in HI titers were 56.2% versus 80% for H1N1 (P = 0.04), 40.6% versus 53.3% for H3N2 (P = 0.31), and 59.4% versus 83.3% for B (P = 0.038). Immune responses for H1N1 and B subunits were significantly lower in patients than controls.

CONCLUSIONS

Influenza vaccine is tolerated well in ALL patients with acceptable but limited immune response compared to healthy controls. These findings support the recommendation for annual influenza vaccination in children with ALL.

Links

Aggregator Full Text

Authors+Show Affiliations

Shahgholi E
Department of Pediatric Hematology/Oncology, Tehran University of Medical Sciences, Tehran, Iran. eshahgholi@sina.tums.ac.ir
Ehsani MA
No affiliation info available
Salamati P
No affiliation info available
Maysamie A
No affiliation info available
Sotoudeh K
No affiliation info available
Mokhtariazad T
No affiliation info available

MeSH

AdolescentChildChild, PreschoolFemaleHumansImmunocompromised HostInfantInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza VaccinesInfluenza, HumanIranMalePrecursor Cell Lymphoblastic Leukemia-LymphomaVaccines, Combined

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20205258

Citation

Shahgholi, Elham, et al. "Immunogenicity of Trivalent Influenza Vaccine in Children With Acute Lymphoblastic Leukemia During Maintenance Therapy." Pediatric Blood & Cancer, vol. 54, no. 5, 2010, pp. 716-20.
Shahgholi E, Ehsani MA, Salamati P, et al. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer. 2010;54(5):716-20.
Shahgholi, E., Ehsani, M. A., Salamati, P., Maysamie, A., Sotoudeh, K., & Mokhtariazad, T. (2010). Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatric Blood & Cancer, 54(5), 716-20. https://doi.org/10.1002/pbc.22421
Shahgholi E, et al. Immunogenicity of Trivalent Influenza Vaccine in Children With Acute Lymphoblastic Leukemia During Maintenance Therapy. Pediatr Blood Cancer. 2010;54(5):716-20. PubMed PMID: 20205258.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. AU - Shahgholi,Elham, AU - Ehsani,Mohammad Ali, AU - Salamati,Payman, AU - Maysamie,Alipasha, AU - Sotoudeh,Kambiz, AU - Mokhtariazad,Talat, PY - 2010/3/6/entrez PY - 2010/3/6/pubmed PY - 2010/4/8/medline SP - 716 EP - 20 JF - Pediatric blood & cancer JO - Pediatr Blood Cancer VL - 54 IS - 5 N2 - PURPOSE: The aim of this study was to assess the immune response of children with acute lymphoblastic leukemia (ALL) to influenza vaccine and to compare it with healthy controls. PROCEDURE: Thirty-two children aged 1-18 years with ALL on maintenance therapy and 30 healthy sibling controls were enrolled in the study. All children were vaccinated with trivalent inactivated influenza vaccine. Hemagglutinin-inhibition (HI) antibody titers were determined in sera of both patient and control groups just before and 4 weeks after vaccination. The ability of each group to mount a protective (> or =40) and/or fourfold titer was measured. RESULTS: The protective response for virus subunits among patients and healthy controls were 43.4% versus 88% for H1N1 (P = 0.04), 63.3% versus 80% for H3N2 antigens (P = 0.06), and 26% versus 73% for B antigen (P = 0.001). Responses for H1N1 and B subunits were significantly lower in patients than controls. In the patient group, the significant response to each virus was demonstrated in the analysis of pre- and post-vaccination geometric mean titer (GMT) (P = 0.001). The percentage of patients and controls with fourfold increase in HI titers were 56.2% versus 80% for H1N1 (P = 0.04), 40.6% versus 53.3% for H3N2 (P = 0.31), and 59.4% versus 83.3% for B (P = 0.038). Immune responses for H1N1 and B subunits were significantly lower in patients than controls. CONCLUSIONS: Influenza vaccine is tolerated well in ALL patients with acceptable but limited immune response compared to healthy controls. These findings support the recommendation for annual influenza vaccination in children with ALL. SN - 1545-5017 UR - https://www.unboundmedicine.com/medline/citation/20205258/Immunogenicity_of_trivalent_influenza_vaccine_in_children_with_acute_lymphoblastic_leukemia_during_maintenance_therapy_ L2 - https://doi.org/10.1002/pbc.22421 DB - PRIME DP - Unbound Medicine ER -